Literature DB >> 24497555

Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations.

Jean-Baptiste Micol1, Omar Abdel-Wahab.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24497555      PMCID： PMC3912947          DOI： 10.3324/haematol.2013.101303

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival.

Authors:  Csaba Bödör; Aline Renneville; Matthew Smith; Aurélie Charazac; Sameena Iqbal; Pascaline Etancelin; Jamie Cavenagh; Michael J Barnett; Karolina Kramarzová; Biju Krishnan; András Matolcsy; Claude Preudhomme; Jude Fitzgibbon; Carolyn Owen
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia.

Authors:  Harriet Holme; Upal Hossain; Michael Kirwan; Amanda Walne; Tom Vulliamy; Inderjeet Dokal
Journal:  Br J Haematol       Date:  2012-04-26       Impact factor: 6.998

3.  Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia.

Authors:  Renée Beekman; Marijke G Valkhof; Mathijs A Sanders; Paulette M H van Strien; Jurgen R Haanstra; Lianne Broeders; Wendy M Geertsma-Kleinekoort; Anjo J P Veerman; Peter J M Valk; Roel G Verhaak; Bob Löwenberg; Ivo P Touw
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

4.  Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome).

Authors:  Pia Ostergaard; Michael A Simpson; Fiona C Connell; Colin G Steward; Glen Brice; Wesley J Woollard; Dimitra Dafou; Tatjana Kilo; Sarah Smithson; Peter Lunt; Victoria A Murday; Shirley Hodgson; Russell Keenan; Daniela T Pilz; Ines Martinez-Corral; Taija Makinen; Peter S Mortimer; Steve Jeffery; Richard C Trembath; Sahar Mansour
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

5.  High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.

Authors:  Marlène Pasquet; Christine Bellanné-Chantelot; Suzanne Tavitian; Naïs Prade; Blandine Beaupain; Olivier Larochelle; Arnaud Petit; Pierre Rohrlich; Christophe Ferrand; Eric Van Den Neste; Hélène A Poirel; Thierry Lamy; Marie Ouachée-Chardin; Véronique Mansat-De Mas; Jill Corre; Christian Récher; Geneviève Plat; Françoise Bachelerie; Jean Donadieu; Eric Delabesse
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

6.  GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome.

Authors:  Amy P Hsu; Kirby D Johnson; E Liana Falcone; Rajendran Sanalkumar; Lauren Sanchez; Dennis D Hickstein; Jennifer Cuellar-Rodriguez; Jacob E Lemieux; Christa S Zerbe; Emery H Bresnick; Steven M Holland
Journal:  Blood       Date:  2013-03-15       Impact factor: 22.113

7.  Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Authors:  Raphaël Itzykson; Olivier Kosmider; Aline Renneville; Véronique Gelsi-Boyer; Manja Meggendorfer; Margot Morabito; Céline Berthon; Lionel Adès; Pierre Fenaux; Odile Beyne-Rauzy; Norbert Vey; Thorsten Braun; Torsten Haferlach; François Dreyfus; Nicholas C P Cross; Claude Preudhomme; Olivier A Bernard; Michaela Fontenay; William Vainchenker; Susanne Schnittger; Daniel Birnbaum; Nathalie Droin; Eric Solary
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

8.  Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency.

Authors:  Rachel Emma Dickinson; Helen Griffin; Venetia Bigley; Louise N Reynard; Rafiqul Hussain; Muzlifah Haniffa; Jeremy H Lakey; Thahira Rahman; Xiao-Nong Wang; Naomi McGovern; Sarah Pagan; Sharon Cookson; David McDonald; Ignatius Chua; Jonathan Wallis; Andrew Cant; Michael Wright; Bernard Keavney; Patrick F Chinnery; John Loughlin; Sophie Hambleton; Mauro Santibanez-Koref; Matthew Collin
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

9.  Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Christopher N Hahn; Chan-Eng Chong; Catherine L Carmichael; Ella J Wilkins; Peter J Brautigan; Xiao-Chun Li; Milena Babic; Ming Lin; Amandine Carmagnac; Young K Lee; Chung H Kok; Lucia Gagliardi; Kathryn L Friend; Paul G Ekert; Carolyn M Butcher; Anna L Brown; Ian D Lewis; L Bik To; Andrew E Timms; Jan Storek; Sarah Moore; Meryl Altree; Robert Escher; Peter G Bardy; Graeme K Suthers; Richard J D'Andrea; Marshall S Horwitz; Hamish S Scott
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

10.  ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

Authors:  Omar Abdel-Wahab; Mazhar Adli; Lindsay M LaFave; Jie Gao; Todd Hricik; Alan H Shih; Suveg Pandey; Jay P Patel; Young Rock Chung; Richard Koche; Fabiana Perna; Xinyang Zhao; Jordan E Taylor; Christopher Y Park; Martin Carroll; Ari Melnick; Stephen D Nimer; Jacob D Jaffe; Iannis Aifantis; Bradley E Bernstein; Ross L Levine
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743
View more
  14 in total

1.  Leveraging premalignant biology for immune-based cancer prevention.

Authors:  Avrum Spira; Mary L Disis; John T Schiller; Eduardo Vilar; Timothy R Rebbeck; Rafael Bejar; Trey Ideker; Janine Arts; Matthew B Yurgelun; Jill P Mesirov; Anjana Rao; Judy Garber; Elizabeth M Jaffee; Scott M Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-16       Impact factor: 11.205

Review 2.  Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael W N Deininger; Jeffrey W Tyner; Eric Solary
Journal:  Nat Rev Cancer       Date:  2017-06-23       Impact factor: 60.716

Review 3.  The Role of Additional Sex Combs-Like Proteins in Cancer.

Authors:  Jean-Baptiste Micol; Omar Abdel-Wahab
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

Review 4.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

5.  Mutational profiling of a MonoMAC syndrome family with GATA2 deficiency.

Authors:  L-W Ding; T Ikezoe; K-T Tan; M Mori; A Mayakonda; W Chien; D-C Lin; Y-Y Jiang; M Lill; H Yang; Q-Y Sun; H P Koeffler
Journal:  Leukemia       Date:  2016-09-29       Impact factor: 11.528

Review 6.  Germline GATA2 Mutation and Bone Marrow Failure.

Authors:  Lisa J McReynolds; Katherine R Calvo; Steven M Holland
Journal:  Hematol Oncol Clin North Am       Date:  2018-05-28       Impact factor: 3.722

Review 7.  Significance of Clonal Mutations in Bone Marrow Failure and Inherited Myelodysplastic Syndrome/Acute Myeloid Leukemia Predisposition Syndromes.

Authors:  Eva J Schaefer; R Coleman Lindsley
Journal:  Hematol Oncol Clin North Am       Date:  2018-05-01       Impact factor: 3.722

Review 8.  Advances in germline predisposition to acute leukaemias and myeloid neoplasms.

Authors:  Jeffery M Klco; Charles G Mullighan
Journal:  Nat Rev Cancer       Date:  2020-12-16       Impact factor: 60.716

Review 9.  Haematopoietic and immune defects associated with GATA2 mutation.

Authors:  Matthew Collin; Rachel Dickinson; Venetia Bigley
Journal:  Br J Haematol       Date:  2015-02-23       Impact factor: 6.998

10.  Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation.

Authors:  Anna Lübking; Sebastian Vosberg; Nikola P Konstandin; Annika Dufour; Alexander Graf; Stefan Krebs; Helmut Blum; Axel Weber; Stig Lenhoff; Mats Ehinger; Karsten Spiekermann; Philipp A Greif; Jörg Cammenga
Journal:  Leuk Res Rep       Date:  2015-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.